As of Oct 21
| +0.30 / +0.90%|
The 9 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 72.00, with a high estimate of 109.00 and a low estimate of 36.00. The median estimate represents a +114.29% increase from the last price of 33.60.
The current consensus among 11 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.